Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

Pacritinib, potent inhibitor of Janus kinase 2 (JAK2), JAK2V617F, and fms-like receptor tyrosine kinase 3, is in Phase III development in myelofibrosis. Among type 1 inhibitors, pacritinib shows a lack of myelosuppression at doses that both inhibit JAK2/signal transducer and activator of transcripti...

Descripción completa

Detalles Bibliográficos
Autores principales: Singer, Jack W, Al-Fayoumi, Suliman, Ma, Haiching, Komrokji, Rami S, Mesa, Ruben, Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993559/
https://www.ncbi.nlm.nih.gov/pubmed/27574472
http://dx.doi.org/10.2147/JEP.S110702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993559/
https://www.ncbi.nlm.nih.gov/pubmed/27574472
http://dx.doi.org/10.2147/JEP.S110702

Ejemplares similares